title: Use of oral montelukast in the treatment of asthma.
abstract: Montelukast, a new leukotriene modifier, has several benefits in the treatment of asthma in adults and children including improved relief of asthma symptoms, rapid onset, a safety profile comparable with placebo, and oral, once-daily dosing means excellent adherence.
authors: Departments of Pulmonary/Immunology and Biostatistics, Merck Research Laboratories, P.O. Box 2000, RY 33-648, Rahway, NJ 07065, USA.
authors: G P
authors: GP
authors: Noonan
authors: B
authors: B
authors: Williams
authors: R
authors: R
authors: Angner
authors: S
authors: S
authors: Lu
authors: B
authors: B
authors: Knorr
authors: T F
authors: TF
authors: Reiss
mesh_terms: D000085:Acetates / Q000008:administration & dosage*; D000284:Administration, Oral; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D016084:Bronchoconstriction; D002648:Child; D002986:Clinical Trials as Topic; D003521:Cyclopropanes; D004347:Drug Interactions; D015444:Exercise; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology; D011804:Quinolines / Q000008:administration & dosage*; D013440:Sulfides
chemical_list: D000085:Acetates; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D018836:Inflammation Mediators; D011804:Quinolines; D013440:Sulfides; C093875:montelukast